Alternative sources of haematopoietic cells including cord blood today and tomorrow. The outlook for cord blood banks – conclusions of the Panel of Experts
Authors:
P. Cetkovský 1; Z. Kořístek 2; J. Starý 3; J. Štěrba 4; P. Žák 5
Authors‘ workplace:
Ústav hematologie a krevní transfuze, Praha
1; Klinika hematoonkologie, Fakultní nemocnice Ostrava, Ostrava
2; Klinika dětské hematologie a onkologie, Fakultní nemocnice Motol, Praha
3; Klinika dětské onkologie, Fakultní nemocnice Brno, Brno
4; IV. interní hematologická klinika, FN Hradec Králové, Hradec Králové
5
Published in:
Transfuze Hematol. dnes,22, 2016, No. 3, p. 210-223.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Most patients who require allogeneic stem cell transplantation do not have a matched sibling donor. A matched unrelated donor is not available for up to 25% of these patients who are thus candidates for allogeneic transplantation using alternative donors: family haploidentical donors, mismatched unrelated donors or cord blood. Thanks to the availability of alternative donors, we are able to transplant almost every patient who requires this treatment modality. The individual types of alternative donors have their specific advantages and disadvantages, both medical and economical. The aim of this publication is to provide a comparison of available alternative donors. The increasing number of haploidentical transplants cannot be ignored and it is obvious that the trend for using alternative donors of hematopoietic stem cells is changing. The importance of cord blood is gradually decreasing and this is affecting the position and economic situation of public cord blood banks. Therefore, the conclusions made by the panel of experts also deal with the future use of umbilical cord blood and discuss various concepts of cord blood banks.
KEY WORDS:
haematopoietic cells – allogeneic transplantation – alternative donors – haploidentical transplantation – unrelated donor – HLA – umbilical cord blood – cord blood bank – hybrid bank
Sources
1. Ballen KK, King RJ, Chitphakdithai P, et al. The national marrow donor program 20 years of unrelated donor hematopoietic cell transplanta-tion. Biol Blood Marrow Transplant 2008; 14 (9 Suppl): 2–7.
2. Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for haematopoietic stem-cell grafts in the U.S. registry. N Engl J Med 2014; 371: 339–348.
3. Luznik L, O’Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650.
4. Anasetti C, Logan BR, Lee SJ, et al. Blood and Marrow Transplant Clinical Trials Network. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367: 1487–1496.
5. Kekre N, Antin JH. Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood 2014; 124: 334–343.
6. Raiola AM, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 2013; 19: 117–122.
7. Rocha V, Labopin M, Sanz G, et al. Acute Leukemia Working Party of European Blood and Marrow Transplant Group; Eurocord-Netcord Registry. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351(22): 2276–2285.
8. Sanz J, Sanz MA, Saavedra S, et al. Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant 2010; 16: 86–94.
9. Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011; 118: 282–288.
10. Ballen KK, Spitzer TR, Yeap BY, et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 2007; 13: 82–89.
11. Brunstein CG, Barker JN, Weisdorf DJ, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007; 110: 3064–3070.
12. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001; 344: 1815–1822.
13. Barker JN, Scaradavou A, Stevens CE. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood 2010; 115: 1843–1849.
14. Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002; 100: 1611–1618.
15. Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105: 1343–1347.
16. Avery S, Shi W, Lubin M, et al. Influence of infused cell dose and HLA--match on engraftment after double unit cord blood allografts. Blood 2011; 117: 3277–3285.
17. Ponce DM, Zheng J, Gonzales AM, et al. Reduced late mortality risk contributes to similar survival after double-unit cord blood transplant compared with related and unrelated donor hematopoietic stem cell transplant. Biol Blood Marrow Transplant 2011; 17: 1316–1326.
18. Scaradavou A, Brunstein CG, Eapen M, et al. Double unit grafts successfully extend the application of umbilical cord blood transplanta-tion in adults with acute leukemia. Blood 2013; 121: 752–758.
19. Ruggeri A, Labopin M, Sanz G, et al. Eurocord, Cord Blood Committee of Cellular Therapy and Immunobiology working party-EBMT; ALWP-EBMT study. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. Leukemia 2015; 29: 1891–1900.
20. Baron F, Labopin M, Ruggeri A, et al. Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood – a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation. J Hematol Oncol 2015; 8: 107–118.
21. Atsuta Y, Suzuki R, Nagamura-Inoue T, et al. Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood 2009; 113: 1631–1638.
22. Brunstein CG, Eapen M, Ahn KW, et al. Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood 2012; 119: 5591–5598.
23. Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010; 11: 653–660.
24. Peffault de Latour R, Brunstein CG, Porcher R, et al. Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia. Biol Blood Marrow Transplant 2013; 19: 1355–1360.
25. Weisdorf D, Eapen M, Ruggeri A, et al. Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis. Biol Blood Marrow Transplant 2014; 20: 816–822.
26. Jacobson CA, Turki AT, McDonough SM, et al. Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2012; 18: 565–574.
27. Granier C, Biard L, Masson E, et al. Impact of the source of hematopoietic stem cell in unrelated transplants: comparison between 10/10, 9/10-HLA matched donors and cord blood. Am J Hematol 2015; 90: 897–903.
28. Brunstein CG, Gutman JA, Weisdorf DJ, et al. Allogeneic hemato-poietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010; 116: 4693–4699.
29. Weisdorf D, Cooley S, Devine S, et al. T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome. Biol Blood Marrow Transplant 2012; 18: 937–943.
30. Devillier R, Fürst S, Crocchiolo R, et al. A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor. Am J Hematol 2014; 89: 83–87.
31. Kumar A, Mhaskar AR, Reljic T, et al. Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia 2012; 26: 582–588.
32. Bashey A, Zhang X, Sizemore CA, et al. T-cell-replete HLA--haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 2013; 31: 1310–1316.
33. Raiola AM, Dominietto A, di Grazia C, et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant 2014; 20: 1573–1579.
34. Di Stasi A, Milton DR, Poon LM, et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant 2014; 20: 1975–1981.
35. Giralt S, Logan B, Rizzo D, et al. Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. Biol Blood Marrow Transplant 2007; 13: 844–852.
36. Mehta RS, Saliba RM, Chen J, et al. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol 2016; 173: 444–455.
37. Bart T, Boo M, Balabanova S, et al. Impact of selection of cord blood units from the United States and swiss registries on the cost of banking operations. Transfus Med Hemother 2013; 40: 14–20.
38. Majhail NS, Mothukuri JM, Brunstein CG, Weisdorf DJ. Costs of haematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. Biol Blood Marrow Transplant 2009; 15: 564–573.
39. Cordonnier C, Maury S, Esperou H, et al. Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia. Bone Marrow Transplant 2005; 36: 649–654.
40. Passweg JR, Baldomero H, Bader P, et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant 2016; 51: 786–792.
41. Passweg JR, Baldomero H, Bader P, et al. European Society for Blood and Marrow Transplantation (EBMT). Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant 2015; 50: 476–482.
42. Anasetti C. Use of alternative donors for allogeneic stem cell transplantation. Hematology Am Soc Hematol Educ Program 2015; 2015: 220–224.
43. Broxmeyer HE, Farag S. Background and future considerations for human cord blood hematopoietic cell transplantation, including economic concerns. Stem Cells Dev 2013; 22 (Suppl 1): 103–110.
44. Zdroj: www.bmdw.org.
45. Magalon J, Maiers M, Kurtzberg J, et al. Banking or Bankrupting: Strategies for Sustaining the Economic Future of Public Cord Blood Banks. PLoS ONE 2015; 10: e0143440.
46. WMDA annual report cord blood Bank/Registries. 2014.
47. Farag SS, Srivastava S, Messina-Graham S, et al. In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies. Stem Cells Dev 2013; 22: 1007–1015.
48. Cutler C, Multani P, Robbins D, et al. Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood 2013; 122: 3074–3081.
49. Popat U, Mehta RS, Rezvani K, et al. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 2015; 125: 2885–2892.
50. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010; 16: 232–237.
51. de Lima M, McNiece I, Robinson SN, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 2012; 367: 2305–2315.
52. Horwitz ME, Chao NJ, Rizzieri DA, et al. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. J Clin Invest 2014; 124: 3121–3128.
53. Rocha V, Labopin M, Ruggeri A, et al. Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies. Transplantation 2013; 95: 1284–1291.
54. Liu H, Rich ES, Godley L, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood 2011; 118: 6438–6445.
55. Le plan greffe 2012-2016. l’Agence de la biomédecine. Agence relevant du ministère de la Santé, France. 2012.
56. Matsumoto MM, Matthews KR. A need for renewed and cohesive US policy on cord blood banking. Stem Cell Rev 2015; 11: 789–797.
57. Ballen KK, Verter F, Kurtzberg J. Umbilical cord blood donation: public or private? Bone Marrow Transplant 2015; 50: 1271–1278.
58. Passweg JR, Baldomero H, Peters C, et al. European Society for Blood and Marrow Transplantation EBMT. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant 2014; 49: 744–750.
59. Zdroj: www.parentsguidecordblood.org .
60. Gluckman E, Ruggeri A, Rocha V, et al. Eurocord, Netcord, World Marrow Donor Association and National Marrow Donor Program. Family-directed umbilical cord blood banking. Haematologica 2011; 96: 1700–1707.
61. Reed W, Smith R, Dekovic F, et al. Comprehensive banking of sibling donor cord blood for children with malignant and nonmalignant disease. Blood 2003; 101: 351–357.
62. Manegold G, Meyer-Monard S, Tichelli A, Granado C, Hösli I, Troeger C. Controversies in hybrid banking: attitudes of Swiss public umbilical cord blood donors toward private and public banking. Arch Gynecol Obstet 2011; 284: 99–104.
63. Wagner AM, Krenger W, Suter E, en Hassem D, Surbek DV. High acceptance rate of hybrid allogeneic-autologous umbilical cord blood banking among actual and potential Swiss donors. Transfusion 2013; 53: 1510–1590.
64. Katz G. Industrial economics of cord blood banks. In: Cord Blood Stem Cells Medicine. Edit.: Stavropoulos-Giokas, Charron, Navarrete. Elsevier 2015. Kapitola 24, s. 325–340.
65. Corsano B, Sacchini D, Šuleková M, Minacori R, Refolo P, Spagnolo AG. Allogeneic versus autologous: ethical issues in umbilical cord blood use. Eur J Bioethics 2015; 6: 67–85.
66. O’Connor MAC, Samuel G, Jordens CFC, Kerridge IH. Umbilical cord blood banking: Beyond the public-private divide. J Law Med 2012; 19: 512–516.
67. Burroughs L, Woolfrey A. Hematopoietic cell transplantation for treatment of primary immune deficiencies. Cell Ther Transplant 2010; 2: 10.3205/ctt-2010-en-000077.01.
68. Aldenhoven M, Jones SA, Bonney D, et al. Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines. Biol Blood Marrow Transplant 2015; 21: 1106–1109.
69. Aldenhoven M, Kurtzberg J. Cord blood is the optimal graft source for the treatment of pediatric patients with lysosomal storage diseases: clinical outcomes and future directions. Cytotherapy 2015; 17: 765–774.
70. Malinová V, Honzík T. Lysosomální onemocnění – současné možnosti diagnostiky a terapie. Pediatr praxi 2013; 14: 157–160.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2016 Issue 3
Most read in this issue
- Alpha-thalassemia in 45 Czech and 37 immigrant families: review of the literature and molecular diagnosis
- Diagnosis and prognostic factors in mantle cell lymphoma
- Immunogenetic factors influencing red blood cell alloimmunization
- Correlation analysis of standard Bethesda method versus modified Nijmegen assay in detecting factor VIII inhibitors, and impact of marginal titer inhibitors on FVIII pharmacodynamics and pharmacokinetics by patients with hemophilia A